上海医药:获得溴吡斯的明口服溶液药品注册证书
Zheng Quan Shi Bao Wang·2026-01-09 08:45

Group 1 - The core point of the article is that Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of Bromides of the Ming oral solution, which is used to treat myasthenia gravis [1] - The drug was originally developed by BAUSCH and was first launched in the United States in 1965 [1] - As of the announcement date, the company has invested approximately 2.3174 million yuan in the research and development of this drug [1] Group 2 - There are currently no other companies in China that have this drug listed for sale [1]

Shanghai Pharma-上海医药:获得溴吡斯的明口服溶液药品注册证书 - Reportify